These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state. Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334 [TBL] [Abstract][Full Text] [Related]
6. Effect of nonsteroidal antiandrogen monotherapy versus castration therapy on neuroendocrine differentiation in prostate carcinoma. Sciarra A; Di Silverio F Urology; 2004 Mar; 63(3):523-7. PubMed ID: 15028450 [TBL] [Abstract][Full Text] [Related]
7. Insulin-like growth factor 1, chromogranin A and prostate specific antigen serum levels in prostate cancer patients and controls. Marszalek M; Wachter J; Ponholzer A; Leitha T; Rauchenwald M; Madersbacher S Eur Urol; 2005 Jul; 48(1):34-9. PubMed ID: 15967249 [TBL] [Abstract][Full Text] [Related]
8. Chromogranin A and biochemical progression-free survival in prostate adenocarcinomas submitted to radical prostatectomy. Alessandro S; Vincenzo G; Maria AG; Stefano S; Alessandro G; Salvatore M; Vincenzo T; Franco DS Endocr Relat Cancer; 2007 Sep; 14(3):625-32. PubMed ID: 17914093 [TBL] [Abstract][Full Text] [Related]
9. Plasma neuroendocrine markers in patients with benign prostatic hyperplasia and prostatic carcinoma. Cussenot O; Villette JM; Valeri A; Cariou G; Desgrandchamps F; Cortesse A; Meria P; Teillac P; Fiet J; Le Duc A J Urol; 1996 Apr; 155(4):1340-3. PubMed ID: 8632569 [TBL] [Abstract][Full Text] [Related]
10. Plasma chromogranin A in prostatic carcinoma and neuroendocrine tumors. Kimura N; Hoshi S; Takahashi M; Takeha S; Shizawa S; Nagura H J Urol; 1997 Feb; 157(2):565-8. PubMed ID: 8996358 [TBL] [Abstract][Full Text] [Related]
11. Prognostic value of serum markers for prostate cancer. Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759 [TBL] [Abstract][Full Text] [Related]
12. Evaluation and clinical value of neuroendocrine differentiation in human prostatic tumors. Cussenot O; Villette JM; Cochand-Priollet B; Berthon P Prostate Suppl; 1998; 8():43-51. PubMed ID: 9690663 [TBL] [Abstract][Full Text] [Related]
13. Oral estramustine therapy in serum chromogranin A-positive stage D3 prostate cancer patients. Zaky Ahel M; Kovacic K; Kraljic I; Tarle M Anticancer Res; 2001; 21(2B):1475-9. PubMed ID: 11396235 [TBL] [Abstract][Full Text] [Related]
14. Changes in chromogranin a serum levels during endocrine therapy in metastatic prostate cancer patients. Sasaki T; Komiya A; Suzuki H; Shimbo M; Ueda T; Akakura K; Ichikawa T Eur Urol; 2005 Aug; 48(2):224-9; discussion 229-30. PubMed ID: 16005374 [TBL] [Abstract][Full Text] [Related]
15. Prospective study of the ability of serial measurements of serum chromogranin A and gastrin to detect changes in tumor burden in patients with gastrinomas. Abou-Saif A; Gibril F; Ojeaburu JV; Bashir S; Entsuah LK; Asgharian B; Jensen RT Cancer; 2003 Jul; 98(2):249-61. PubMed ID: 12872342 [TBL] [Abstract][Full Text] [Related]
16. Acquired neuroendocrine-positivity during maximal androgen blockade in prostate cancer patients. Tarle M; Ahel MZ; Kovacić K Anticancer Res; 2002; 22(4):2525-9. PubMed ID: 12174956 [TBL] [Abstract][Full Text] [Related]
17. Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. Cabrespine A; Guy L; Gachon F; Curé H; Chollet P; Bay JO J Urol; 2006 Apr; 175(4):1347-52. PubMed ID: 16515996 [TBL] [Abstract][Full Text] [Related]
18. [Combined assay of serum prostate specific antigen and chromogranin A helps diagnosis of prostate cancer]. Sun CC; Zheng W; Kong CZ; Wang X; Yang CM Zhonghua Nan Ke Xue; 2006 Oct; 12(10):904-5, 909. PubMed ID: 17121020 [TBL] [Abstract][Full Text] [Related]
19. The chromogranin-A (CgA) in prostate cancer. Ranno S; Motta M; Rampello E; Risino C; Bennati E; Malaguarnera M Arch Gerontol Geriatr; 2006; 43(1):117-26. PubMed ID: 16280180 [TBL] [Abstract][Full Text] [Related]
20. Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma. Sciarra A; Monti S; Gentile V; Mariotti G; Cardi A; Voria G; Lucera R; Di Silverio F Prostate; 2003 May; 55(3):168-79. PubMed ID: 12692782 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]